Paradigm Diagnostics PCDx Tests
Paradigm Diagnostics said that all of its Paradigm Cancer Diagnostic (PCDx) tests ordered for lung cancer patients now also include 17 fusions, as well as EGFR and MET skipping events. The fusions include: ALK, AXL, BRAF, CCND1, FGFR1, FGFR2, FGFR3, MET, NGR1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1 and THADA. The fusion panel may also be ordered as an add-on for any PCDx patients and will be delivered within in the company's standard five-day turnaround time. The assay uses anchored PCR technology on RNA to detect known and novel fusions with high sensitivity with a tissue requirement of 4 percent or greater tumor content in a single core needle biopsy or fine needle aspirate.